Wall Street Zen upgraded shares of Omeros (NASDAQ:OMER – Free Report) from a hold rating to a buy rating in a research note issued to investors on Saturday.
OMER has been the subject of a number of other reports. Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday, April 21st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $38.00.
Read Our Latest Stock Report on OMER
Omeros Price Performance
Omeros (NASDAQ:OMER – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analysts’ expectations of $12.69 million. Equities analysts anticipate that Omeros will post -0.37 EPS for the current fiscal year.
Insider Transactions at Omeros
In other news, Director Thomas J. Cable sold 7,500 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total transaction of $87,075.00. Following the completion of the sale, the director owned 35,067 shares of the company’s stock, valued at $407,127.87. This represents a 17.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is currently owned by company insiders.
Institutional Trading of Omeros
A number of hedge funds have recently bought and sold shares of the business. State of Wyoming purchased a new stake in shares of Omeros in the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Omeros during the fourth quarter worth $33,000. Assetmark Inc. purchased a new stake in Omeros in the 1st quarter valued at $38,000. Arax Advisory Partners grew its holdings in Omeros by 56.4% in the 4th quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 1,894 shares in the last quarter. Finally, International Assets Investment Management LLC increased its stake in shares of Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 800 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.
More Omeros News
Here are the key news stories impacting Omeros this week:
- Positive Sentiment: Omeros reported second-quarter earnings of $0.02 per share, substantially ahead of the expected $0.27 loss, while revenue of $28.53 million more than doubled the $12.69 million consensus estimate. The earnings beat was the primary catalyst for the recent advance. Omeros Q2 Earnings and Revenues Beat Estimates
- Positive Sentiment: Management highlighted a strong launch for YARTEMLEA, along with debt reduction and potential share repurchases. Analysts also pointed to reduced C5 competition as a favorable factor for the company’s commercial outlook. OMER Stock Soars After YARTEMLEA Momentum
- Positive Sentiment: H.C. Wainwright maintained its Buy rating and $33 price target, citing YARTEMLEA’s strong launch and a more favorable competitive environment. The target implies substantial potential upside if the commercial momentum continues. Omeros Buy Rating and $33 Price Target
- Neutral Sentiment: Omeros expanded its board from eight to nine members by appointing veteran investor Joseph Schocken. The appointment could add governance and investment expertise, but its near-term financial impact is unclear. Omeros Appoints Joseph Schocken to Board
- Neutral Sentiment: Trading in OMER call options increased sharply, indicating heightened speculative interest and bullish positioning, but options activity alone does not confirm a sustained fundamental move.
- Negative Sentiment: H.C. Wainwright lowered its long-term EPS forecasts to $3.59 for fiscal 2029 from $3.95 and to $4.62 for fiscal 2030 from $5.00. Although the firm retained its Buy rating, the revisions signal some caution about the pace of future earnings growth.
Omeros Company Profile
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Stories
- Five stocks we like better than Omeros
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
